Impact of Bioelectrical Impedance-Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Hypervolemia and vitamin D deficiency occur frequently in patients receiving peritoneal dialysis and may contribute to left ventricular (LV) hypertrophy.

The effect of bioelectrical impedance analysis (BIA)-guided volume management or vitamin D supplementation on LV mass among those receiving peritoneal dialysis is uncertain.

Why It Was Studied

Relatively small sample size with larger than expected variation in change in LV mass.

Unrestricted Baxter International extramural grant and the Kidney Foundation of Canada.

Who Took Part

Sixty-five patients receiving maintenance peritoneal dialysis.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Two-by-two factorial randomized controlled trial.

What Was Measured

Topics PubMed links to this paper include Cholecalciferol, Dietary Supplements, Electric Impedance, Hypertrophy, Left Ventricular, Peritoneal Dialysis, Vitamin D and Vitamin D Deficiency.

The authors tagged it with the keywords 25-hydroxyvitamin D, Bioelectrical impedance analysis (BIA), cardiac magnetic resonance (CMR), cardiovascular disease (CVD), end-stage renal disease (ESRD) and fluid management.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.